Login / Signup

Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.

Samuel Dagogo-JackRobert FrederichJie LiuChristopher P CannonHarry ShiDavid Z I CherneyFrancesco CosentinoUrszula MasiukiewiczIra GantzRichard E Pratley
Published in: The Journal of clinical endocrinology and metabolism (2023)
In VERTIS CV patients, ertugliflozin reduced the likelihood of insulin initiation, delayed the time to insulin initiation by up to ∼1.8 years, and reduced insulin dose requirements vs placebo, without increasing hypoglycemia events.
Keyphrases
  • type diabetes
  • glycemic control
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • prognostic factors
  • peritoneal dialysis
  • metabolic syndrome
  • insulin resistance
  • double blind
  • phase iii